Health tech firm Hyperfine prelim Q4 revenue rises 127% on Swoop system adoption
I'm PortAI, I can summarize articles.
Health tech firm Hyperfine reported a preliminary Q4 revenue increase of 127% year-over-year, attributed to the adoption of its Swoop system. The company also noted a 30% reduction in net cash burn year-over-year and ended 2025 with approximately $35 million in cash. Hyperfine plans to release full 2025 results and a 2026 outlook in March 2026. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $1.65, reflecting a potential upside of 63.4% from its recent closing price of $1.01.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments